2011

Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd A. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011; 12: 1504-1513.

Airaksinen K, Mäkelä JP, Taulu S, Ahonen A, Nurminen J, Schnitzler A, Pekkonen E. Effects of DBS on auditory and somatosensory processing in Parkinson's disease. Human Brain Mapping 2011; 32: 1091-1099.

Aktas O, Hartung HP. Beyond axonal transection: Hippocampal damage in Multiple Sclerosis. Annals of Neurology 2011; 69: 433-436.

Aktas O, Ingwersen J, Kieseier B, Küry P, Hohlfeld R, Hartung HP. Orales Fingolimod bei Multipler Sklerose: Therapeutische Modulation des Sphingosin-1-Phosphat-Systems. Nervenarzt2011; 82: 215-225.

Articus K, Baier M, Tracik F, Kühn F, Preuß UW, Kurz A. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. International Journal of Clinical Practice 2011; 65: 790-796.

Barbe MT, Liebhart L, Runge M, Pauls KA, Wojtecki L, Schnitzler A, Allert N, Fink GR, Sturm V, Maarouf M, Timmermann L. Deep brain stimulation in the nucleus ventralis intermedius in patients with essential tremor: habituation of tremor suppression. Journal of Neurology2011; 258: 434-439.

Barbe MT, Liebhart L, Runge M, Deyng J, Florin E, Wojtecki L, Schnitzler A, Allert N, Sturm V, Fink GR, Maarouf M, Timmermann L. Deep brain stimulation of the ventral intermediate nucleus in patients with essential tremor: Stimulation below intercommissural line is more efficient but equally effective as stimulation above. Experimental Neurology 2011; 230: 131-137.

Benecke R, Heinze A, Reichel G, Hefter H, Göbel H; Dysport myofascial pain study group. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections? Pain Medicine 2011; 12: 1607-1614.

Birlea M, Arendt G, Orhan E, Schmid DS, Bellini WJ, Schmidt C, Gilden D, Cohrs RJ. Subclinical reactivation of varicella zoster virus in all stages of HIV infection. Journal of Neurological Sciences 2011; 304: 22-24.

Bischof J, Müller A, Fänder M, Knippschild U, Fischer D. Neurite outgrowth of mature retinal ganglion cells and PC12 cells requires activity of CK1 delta and epsilon. PlosOne 2011; 6: e20857.

Böttcher C, Warnke C, Macht S, Hartung HP, Kieseier BC. An interesting case of nuchal rigidity. Canadian Journal of Neurological Sciences 2011; 38: 516-517.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD, PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-2022.

Bräutigam L, Schütte LD, Godoy JR, Prozorovski T, Gellert M, Hauptmann G, Holmgren A, Lillig CH, Berndt C. Vertebrate-specific glutaredoxin is essential for brain development.Proceedings of the National Academy of Sciences of the Unites States of America 2011; 108: 20532-20537.

Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, Martin R, Aktas O, Paul F, Schippling S. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134: e193.

Buck D, Cepok S, Hoffmann S, Grummel V, Jochim A, Berthele A, Hartung HP, Wassmuth R, Hemmer B. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Archives of Neurology 2011; 68: 480-487.

Buetefisch CM, Heger R, Schicks W, Seitz RJ. Hebbian-type stimulation during robot-assisted training in patients with stroke. Neurorehabilitation & Neural Repair 2011; 25: 645-655.

Carey LM, Abbott DF, Harvey MR, Puce A, Seitz RJ, Donnan GA. Relationship between touch impairment and brain activation after lesions of subcortical and cortical somatosensory regions. Neurorehabilitation and Neural Repair 2011; 25: 443-457.

Correia de Sa JC, Airas L, Bartholome E, Grigoriadis N, Hillert J, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC. Symptomatic therapy in multiple sclerosis - a review for a multimodal approach in clinical practice. Therapeutic Advances in Neurological Disorders 2011; 4: 139-168.

Daniels C, Krack P, Volkmann J, Pinsker MO, Kloss M, Tronnier V Schnitzler A, Wojtecki L, Bötzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G, Witt K. Is the improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable? Movement Disorders 2011; 26: 2516-2521.

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; for the GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology 2011; 18: 69-77.

Dihné M, Hartung HP, Seitz RJ. Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations. Stroke 2011; 42: 2342-2350.

Dittmer S, Kovacs Z, Yuan SH, Siszler G, Kögl M, Summer H, Geerts A, Golz S, Shioda T, Methner A. TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex. Journal of Cell Science 2011; 124: 252-260.

Dohle C, Stephan KM, Valvoda JT, Hosseiny O, Tellmann L, Kuhlen T, Seitz RJ, Freund HJ. Representation of virtual arm movements in precuneus. Experimental Brain Research 2011; 208: 543-555.

Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. Interferon (beta)-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011; 76: 1222-1228.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011; 77: 1551-1560.

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Soelberg P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; Clarity Study Group. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the Clarity study; a post-hoc and subgroup analysis. Lancet Neurology 2011; 10: 329-336.

Gliem M, Panayotopoulos D, Feindt P, Heikaus S, Fleisch MC, Seitz RJ. Cerebellar degeneration as presenting symptom of recurrent endometrial stromal sarcoma with sex-cord elements. Case Reports in Neurology 2011; 3: 54-61.

Grimpe B. Deoxyribozymes: new therapeutics to treat central nervous system disorders. Frontiers in Molecular Neuroscience 2011; 4:25.

Groiss SJ, Siebler M, Schnitzler A. Full recovery of adult onset opsoclonus myoclonus syndrome after early immunotherpy: A case report. Movement Disoders 2011; 26: 1805-1807.

Groiss SJ, Elben S, Reck C, Voges J, Wojtecki L, Schnitzler A. Local field potential oscillations of the globus pallidus in Huntington's disease. Movement Disoders 2011; 26: 2577-2578.

Hartmann CJ, Leube B, Wojtecki L, Betz B, Groiss SJ, Bauer P, Schnitzler A, Südmeyer M. A novel mutation of the SGCE-gene in a German family with myoclonus-dystonia syndrome. Journal of Neurology 2011; 258: 1186-1188.

Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurology 2011; 10: 293-295.

Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics 2011; 11: 351-362.

Hartung HP, Lehmann HC, Willison HJ. Peripheral neuropathies: Establishing common clinical research standards for CIDP. Nature Reviews Neurology 2011; 7: 250-251.

Hartung HP, Kieseier BC, Lehmann HC. Neuromuskuläre Erkrankungen bei Intensivpatienten. In: Burchardi, Larsen, Kuhlen, Muhl, Jauch, Schölmerich (eds.) Intensivmedizin. 11. Aufl. Springer Medizin Verlag, Heidelberg, 2011; 701-711.

Hartung HP, Lehmann HC, Kieseier BC, Hughes R.A Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System2011; 16: 75-83.

Hartung HP. Impact of mobility impairment in multiple sclerosis 1 - healthcare professionals' perspectives. European Neurological Review 2011; 6: 110-114.

Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011; 77: 835-843.

Hartung HP, Berger J, Wiendl H, Meier U, Stangel M, Aktas O, Kieseier BC, Radü EW, Buttmann M, Gold R; für die Teilnehmer eines Expertenmeetings. Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings. Aktuelle Neurologie 2011; 38: 2-11.

Haupts MR, Meyer-Schwickerath R, Hacker A, Haug C, Fink F, Seidel D, Hartung HP. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology 2011; 76: 2131; author reply 2131-2132.

Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, Hartung HP, Thiesen HJ, Zettl UK. Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS ONE 2011; 6: e29648.

Hefter H, Kupsch A, Müngersdorf M, Paus S, Stenner A, Jost W; on behalf of the Dysport Cervical Dystonia Study Group. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJ Open 2011; 2: e000196.

Henke N, Lisak DA, Schneider L, Habicht J, Pergande M, Methner A. The ancient cell death suppressor BAX inhibitor-1. Cell Calcium 2011; 50: 251-260.

Hirschmann J, Ozkurt TE, Butz M, Homburger M, Elben S, Hartmann CJ, Vesper J, Wojtecki L, Schnitzler A. Distinct oscillatory STN-cortical loops revealed by simultaneous MEG and local field potential recordings in patients with Parkinson´s disease. Neuroimage 2011; 55: 1159-1168.

Huehnchen P, Prozorovski T, Klaissle P, Lesemann A, Ingwersen J, Wolf SA, Kupsch A, Aktas O, Steiner B. Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. Glia 2011; 59: 132-142.

Hughes R, Hartung HP. Assessing the value of plasma exchange in neurology. Nature Reviews Neuroscience 2011; 7: 309-10.

Iwaniuk KM, Schira J, Weinhold S, Jung M, Adjaye J, Müller HW. Wernet P, Trompeter HI. Network-like impact of microRNAs on neuronal lineage differentiation of unrestricted somatic stem cells from human cord blood (USSC). Stem Cells2011; 20: 1383-1394.

Jaerve A, Schiwy N, Schmitz C, Müller HW. Differential effect of aging on axon sprouting and regenerative growth in spinal cord injury. Experimental Neurology 2011; 231: 284-294.

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology 2011; 10: 745-758.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; on behalf of the TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS Study Group. Lancet Neurology2011; 10: 520-529.

Kieseier BC, Wiendl H, Hartung HP, Leussink VI, Stüve O. Risks and benefits of multiple sclerosis therapies: need for continual assessment? Current Opinion in Neurology 2011; 24: 238-243.

Kieseier BC, Jeffery DR. Chemotherapeutics in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders 2011; 3: 277-291.

Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis - old versus new. Nature Reviews Neurology 2011; 7: 255-262.

Kieseier BC. The mechanism of action of interferon beta in relapsing multiple sclerosis. CNS Drugs 2011; 25: 491-502

Kieseier BC, Wiendl H. Transforming clinical trials into practical reality (Editorial). Lancet Neurology 2011; 10: 493-494.

Kieseier BC, Stüve O. Multiple sclerosis: Combination therapy in MS - still a valid strategy (Editorial). Nature Reviews Neurology 2011; 7: 659-660.

Kieseier BC. Treatment strategies in multiple sclerosis: weighing the benefits and risks. In: Ziemssen, Tintoré (eds.) A new era in Multiple Sclerosis: New considerations for therapeutic approaches. Elsevier Masson, 2011, pp 69-83.

Klotz L, Gold R, Hemmer B, Korn T, Zipp F, Hohlfeld R, Kieseier BC, Wiendl HW. Diagnostik der Multiplen Sklerose: 2010 Revision der McDonald Kriterien. Nervenarzt 2011; 82: 1302-1309.

Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease - can we wrap it up? Brain 2011; 134: 1882-1900.

Kremer D, Aktas O, Hartung HP, Küry P. The complex world of oligodendroglial differentiation inhibitors. Annals of Neurology 2011; 69: 602-618.

Kruse F, Bosse F, Vogelaar CF, Brazda N, Küry P, Gasis M, Müller HW. Cortical gene expression in spinal cord injury and repair: insight into the functional complexity of the neural regeneration program. Frontiers in Molecular Neuroscience 2011; 4: 26.

Kuehn CPH, El Majdoub F, Wojtecki L, Hoevels M, Maarouf M. Micromultileaf collimator LINAC radiosurgery for large AVM-related trigeminal neuralgia. Pan Arab Journal of Neurosurgery 2011; 15: 2.

Lalive PH, Häusler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Multiple Sclerosis 2011; 17: 297-302.

Lanzman RS, Kröpil P, Schmitt P, Bi X, Gliem M, Miese FR, Hänggi D, Kamp M, Scherer A, Turowski B, Blondin D. Nonenhanced ECG-gated time-resolved 4D steady-state free precession (SSFP) MR angiography (MRA) for assessment of cerebral collateral flow: comparison with digital subtraction angiography (DSA). European Radiology 2011; 21: 1329-1338.

Latov N, Dalakas M, Vallat JM, Donofrio P, Hartung HP, Toyka KV. Biomarkers in the diagnosis and therapy of CIDP: Proceedings of the Biomarkers Faculty Meeting; June 8-9, 2010, Athens, Greece. Journal of the Peripheral Nervous System 2011; Suppl. 1: 1-2.

Lehmann HC, Chen W, Borzan J, Mankowski J, Höke A. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy. Annals of Neurology 2011; 69: 100-110.

Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies. Journal of Neuroimmunology 2011; 231: 61-69.

Liakakis G, Nickel J, Seitz RJ. Diversity of the inferior frontal gyrus-A meta-analysis of neuroimaging studies. Behavioural Brain Research 2011; 225; 341-347.

Lou HC, Joensson M, Biermann-Ruben K, Schnitzler A, Østergaard L, Kjaer TW, Gross J. Recurrent activity in higher order, modality non-specific brain regions: a Granger causality analysis of autobiographic memory retrieval. PLoS One 2011; 6: e22286.

Matzke B, Metze C, Winkelmann A, Grossmann A, Hartung HP, Benecke R, Zettl UK. Severe relapse of multiple sclerosis during plasma exchange treatment. Multiple Sclerosis 2011; 17: 759-762.

Mausberg AK, Dehmel T, Stettner T, Lehmann HC, Sheikh KA, Kieseier BC. Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages. PLoS One 2011; 6: e21223.

Menge T, Hartung HP, Kieseier BC. Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now. Journal of Neurology 2011; 258: 904-907.

Menge T, Kieseier BC. Alemtuzumab: current concepts and application for the treatment of multiple sclerosis. CML - Multiple Sclerosis 2011; 3: 89-104.

Menge T, Lalive PH, von Büdingen HC, Genain CP. Conformational epitopes of myelin oligodendrocyte glycoprotein are targets of potentially pathogenic antibody responses in multiple sclerosis. Journal of Neuroinflammation 2011; 8: 161.

Meyer-Schwickerath R, Haug C, Hacker A, Fink F, Seidel D, Hartung HP, Haupts MR. Intracranial venous pressure is normal in patients with multiple sclerosis. Multiple Sclerosis2011; 17: 637-638.

Meyer zu Hörste G, Miesbach TA, Müller JI, Fledrich R, Stassart RM, Kieseier BC, Coleman MP, Sereda MW. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration. Neurobiology of Disease 2011; 42: 1-8.

Meyer zu Hörste G, Mausberg AK, Müller JI, Lehmann HC, Löber S, Gmeiner P, Hartung HP, Stüve O, Korth C, Kieseier BC. Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules. PLoS One 2011; 6: e21223.

Müller K, Kleiser R, Mechsner F, Seitz RJ. Involvement of area MT in bimanual finger movements in left-handers: an fMRI study. European Journal of Neuroscience 2011; 34: 1301-1309.

Ozkurt TE, Butz M, Homburger M, Elben S, Vesper J, Wojtecki L, Schnitzler A. High frequency oscillations in the subthalamic nucleus: A neurophysiological marker of the motor state in Parkinson's disease. Experimental Neurology 2011; 229: 324-331.

Ozkurt TE, Schnitzler A. A critical note on the definition of phase-amplitude cross-frequency coupling. Journal of Neuroscience Methods 2011; 201: 438-443.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFN-1b and a CCR1-Antagonist; ANZgene Consortium; Gene MSA; International Multiple Sclerosis Genetics Consortium [Sandbrink R, Hartung HP] Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology2011; 70: 897-912

Peters MJ, van Nes SI, Vanhoutte EK, Bakkers M, van Doorn PA, Merkies IS, Faber CG, Hartung HP; PeriNomS Study group. Revised normative values for grip strength with the Jamar dynamometer. Journal of the Peripheral Nervous System 2011; 1: 47-50.

Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; the Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39: 3-12.

Prochnow D, Donell J, Schäfer R, Jörgens S, Hartung HP, Franz M, Seitz RJ. Alexithymia and impaired facial affect recognition in multiple sclerosis. Journal of Neurology 2011; 258: 1683-1688.

Riminton DS, Hartung HP, Reddel SW. Managing the risks of immunosuppression. Current Opinion in Neurology 2011; 3: 217-223.

Rivera FJ, Kraus J, Steffenhagen C, Küry P, Weidner N, Aigner L. Remyelination in multiple sclerosis: The therapeutic potential of neural and mesenchymal stem/progenitor cells. Current Signal Transduction Therapy 2011; 6: 293-313.

Rogers RD, Wielenberg BE, Wojtecki L, Elben S, Campbell-Meiklejohn D, Schnitzler A. Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's Disease. Experimental Neurology 2011; 231: 181-189.

Rolfs A, Martus P, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, Böttcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B, sifap1 Investigators. Protocol and methodology of the Stroke in Young Fabry Patients (sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18-55 years. Cerebrovascular Diseases 2011; 31: 253-262.

Rothgangel AS, Braun SM, Beurskens AJ, Seitz RJ, Wade DT. The clinical aspects of mirror therapy in rehabilitation: a systematic review of the literature. International Journal of Rehabilitation Research 2011; 34: 1-13.

Sabir H, Babor F, Kieseier BC, Mayatepek E, Assmann B. Unilateral facial flushing and sweating after physical exercise: Harlequin syndrome. Klinische Pädiatrie 2011; 223: 90-91.

Saure C, Warnke C, Zohren F, Schröder T, Bruns I, Caddedu RP, Weigelt C, Fischer U, Kobbe G, Hartung HP, Adams O, Kieseier BC, Haas R. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Archives of Neurology 2011; 68: 1428-1431.

Schulz JB, Gerlach M, Gille G, Kuhn W, Müngersdorf M, Riederer P, Südmeyer M, Ludolph A. Basic science in Parkinson's disease: its impact on clinical practice. Journal of Neurology2011; 258: S299-306.

Seitz RJ, Hildebold T, Simeria K. Spontaneous arm movement activity assessed by accelerometry is a marker for early recovery after stroke. Journal of Neurology 2011; 258: 457-463.

Seitz RJ, Gaebel W, Zielasek J. Modular networks involving the medial frontal cortex: towards the development of neuropsychiatry. The World Journal of Biological Psychiatry 2011; 12: 249-259.

Seitz RJ, Oberstrass H, Ringelstein A, Wittsack HJ, Siebler M. Failed recovery from thrombolysis is predicted by the initial diffusion weighted imaging lesion. Cerebrovascular Diseases 2011; 31: 580-587.

Seitz RJ. Zerebrale Reorganisation als Grundlage der postläsionellen Gangerholung. In: Dettmers C, Stephan KM (eds.) Motorische Therapie nach Schlaganfall. Hippokrates Verlag, 2011, Kapitel 20, pp 20-30.

Seitz RJ. Medialer Frontalkortex und subjektive Verhaltenskontrolle. NeuroForum 2011; 17: 128-136.

Sengottuvel V, Leibinger M, Pfreimer M, Andreadaki A, Fischer D. Taxol facilitates axon regeneration in the mature CNS. Journal of Neuroscience 2011; 31: 2688-2699.

Sengottuvel V, Fischer D. Facilitating axon regeneration in the injured CNS by microtubules stabilization. Communicative & Integrative Biology 2011; 4: 391-393.

Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Röther J, Witte OW, Hamann G, Junghans U, Villringer A, Fiebach JB. Safety of Tirofiban in acute ischemic stroke: the SaTIS trial. Stroke 2011; 42: 2388-2392

Sippl C, Bosserhoff AK, Fischer D, Tamm E. Depletion of optineurin in RGC-5 cells derived from retinal neurons cause apoptosis and reduces the secretion of neurotrophins. Experimental Eye Research 2011; 93: 669-680.

Smolianov V, Dehmel T, Vollmar P, Mausberg AK, Kieseier BC, Hemmer B, Hartung HP, Hofstetter HH. Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide. Journal of Neuroinflammation 2011; 8: 59.

Sobottka B, Ziegler U, Kaech A, Becher B, Goebels N. CNS live imaging reveals a new mechanism of myelination: the liquid croissant model. Glia 2011; 59: 1841-1849.

Stangel M, Kieseier BC. Neue Entwicklungen bei CIDP und MMN. Aktuelle Neurologie2011; 38: 284-291.

Stangel M, Gold R; IVIG Konsensusgruppe [Kieseier BC]. Einsatz intravenöser Immunglobuline in der Neurologie - ein Evidenz-basierter Konsensus: Update 2010. Nervenarzt 2011; 82: 415-420.

Steinbeck JA, Henke N, Opatz J, Gruszczynska-Biegala J, Schneider L, Theiss S, Hamacher N, Steinfarz B, Golz S. Brüstle O, Kuznicki J, Methner A. Store-operated calcium entry modulates neuronal network activity in a model of chronic epilepsy. Experimental Neurology2011; 232: 185-194.

Stettner M, Dehmel T, Mausberg AK, Köhne A, Rose C, Kieseier BC. Levetiracetam exhibits protective properties on rat Schwann cells in vitro. Journal of the Peripheral Nervous System 2011; 16: 250-260.

Stevens MF, Werdehausen R, Gaza N, Hermanns H, Kremer D, Bauer I, Küry P, Hollmann MW, Braun S. Midazolam activates the intrinsic pathway of apoptosis independent of benzodiazepine and death receptor signaling. Regional Anesthesia and Pain Medicine2011; 36: 343-349.

Südmeyer M, Maroof P, Saleh A, Hartmann C, Wojtecki L, Schnitzler A. Action tremor caused by olivary cavernoma in Klippel-Trénaunay syndrome micking asymmetric essential tremor. Journal of Neurology 2011; 258: 140-142.

Südmeyer M, Antke C, Zizek T, Beu M, Nikolaus S, Wojtecki L , Schnitzler A, Müller HW. Diagnostic accuracy of combined FP-CIT-, IBZM- and MIBG-scintigraphy in the differential diagnosis of degenerative Parkinsonsim - multidimensional statistical approach. Journal of Nuclear Medicine 2011; 52: 733-740.

Südmeyer M, Wojtecki L, Schnitzler A. Telemedizinische Therapieoptimierung bei Morbus Parkinson. Nervenheilkunde 2011; 30: 36-39.

Südmeyer M, Wojtecki L, Schnitzler A. Therapiestandards in der Behandlung des M. Parkinson. Fortschritte der Neurologie Psychiatrie 2011; 79: 733-743.

The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 [Hartung HP]. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.

Tony HP, Burmester G, Schulze-Koops H, Grünke, Kötter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Müller-Ladner U, König R, Fiehn C, Burgwinkel P, Budde K, Sörensen H, Meurer M, Aringer M, Kieseier BC, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog A, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dörner T; and GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research & Therapy 2011; 13: R75.

Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T, Schira J, Müller HW, Wernet P. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLOSone2011; 6: e16138.

Tumani H, Deisenhammer F, Giovannoni G, Gold R, Hartung HP, Hemmer B, Hohlfeld R, Otto M, Stangel M, Wildemann B, Zettl UK. Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology 2011; 70: 521.

Walter J, Honsek SD, Illes S, Wellen JM, Hartung HP, Rose CR, Dihné M. A new role for interferon gamma in neural stem/precursor cell dysregulation. Molecular Neurodegeneration 2011; 6: 18.

Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zooren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Multiple Sclerosis 2011; 17: 151-156.

Warnke C, Adams O, Gold R, Hartung HP, Hohlfeld R, Wiendl H Kieseier BC. Progressive multifokale Leukenzephalopathie unter Natalizumab. Erste Möglichkeiten einer Risikostratifizierung? Nervenarzt 2011; 82: 475-480.

Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, WiendlKieseier BC. Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab. Empfehlungen zur JC-Virus-Serologie. Nervenarzt 2011; 82: 1314-1319.

Warnke C, Adams O, Hartung HP, Kieseier BC. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of Neurology 2011; 69: 215-216.

Warnke C, Stüve O, Hartung HP, Fogdell-Hahn A, Kieseier BC. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment2011; 7: 519-527.

Warnke C, Andersen K, Hartung HP, Hefter H. Superfizielle Siderose des zentralen Nervensystems bei einem Patienten mit Hämochromatose und Morbus Wilson. Deutsche Medizinische Wochenschrift 2011; 136: 721-724.

Waschbisch A, Sandbrink R, Hartung HP, Kappos L, Schwab S, Pohl C, Wiendl H. Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology 2011; 77: 596-598.

Werdehausen R, Braun S, Hermanns H, Kremer D, Küry P, Hollmann MW, Bauer I, Stevens MF. The influence of adjuvants used in regional anesthesia on lidocaine-induced neurotoxicity in vitro. Regional Anesthesia & Pain Medicine 2011; 36: 436-443.

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Fingolimod treatment for multiple sclerosis patients. What do we do with varicella? Annals of Neurology 2011; 70: 673-674; author reply 674.

Witt K, Daniels C, Krack P, Volkmann J, Pinsker MO, Kloss M, Tronnier V, Schnitzler A, Wojtecki L, Bötzel K, Danek A, Hilker R, Sturm V, Kupsch A, Karner E, Deuschl G. Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease. Journal of Neurological Sciences 2011; 310: 261-266.

Wojtecki L, Vesper J, Schnitzler A. Interleaving programming of subthalamic deep brain stimulation to reduce side effects with good motor outcome in a patient with Parkinson´s disease. Parkinsonism and Related Disorders 2011; 17: 293-294.

Wojtecki L, Timmermann L, Groiss S, Elben S, Reck C, Südmeyer M, Sturm V, Schnitzler A. Long-term time course of affective lability after subthalamic deep brain stimulation electrode implantation. Neurocase 2011; 17: 527-532.

Wojtecki L, Elben S, Timmermann L, Reck C, Maarouf M, Jörgens S, Ploner M, Südmeyer M, Groiss SJ, Sturm V, Niedeggen M, Schnitzler A. Modulation of human time processing by subthalamic deep brain stimulation. PLoS One 2011; 6: e24589.

Wojtecki L, Schnitzler A. Speech arrest after sleeping on the left body side. British Journal of Neurosurgery 2011; 25: 346.

Wojtecki L, Hartmann C, Lee J-I, Südmeyer M, Schnitzler A. Symptomatic cervical dyskinesia with porencephalic cyst, hydrocephalus and leucencephalopathy. Clinical Neurology & Neurosurgery 2011; 113: 603-605.

Wuerfel E, Smyth M, Schellenberger E, Glumm J, Prozorovski T, Aktas O, Schulze-Topphoff U, Schnorr J, Wagner S, Taupitz M, Infante C, Wuerfel J. Electrostatically stabilized magnetic nanoparticles - an optimized protocol to label murine T cells for in vivo MRI. Frontiers in Multiple Sclerosis and Neuroimmunology 2011; 2: 72.

Zhang G, Lehmann HC, Manoharan S, Hashmi M, Shim S, Ming GL, Schnaar RL, Lopez PH, Bogdanova N, Sheikh KA. Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth. Journal of Neuroscience 2011; 31: 1664-1675.

MediathekInformation und Wissen
LageplanSo finden Sie uns